4.6 Article

Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines

期刊

BMC CANCER
卷 8, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/1471-2407-8-300

关键词

-

类别

资金

  1. VZ MSM [0021622415]
  2. IGA MZCR [NR/9125-4 2006]
  3. GACR [204/08/H054]

向作者/读者索取更多资源

Background: Nestin was originally identified as a class VI intermediate filament protein that is expressed in stem cells and progenitor cells in the mammalian CNS during development. This protein is replaced in the adult organism by other intermediate filament proteins; however, nestin may be re-expressed under certain pathological conditions such as ischemia, inflammation, brain injury, and neoplastic transformation. Nestin has been detected in many kinds of tumors, especially in tumors derived from the CNS. Co-expression of nestin and the CD133 surface molecule is considered to be a marker for cancer stem cells in neurogenic tumors. Our work was aimed at a detailed study of nestin expression in osteosarcomas and osteosarcoma-derived cell lines. Methods: Using immunodetection methods, we examined nestin in tumor tissue samples from 18 patients with osteosarcomas. We also successfully established permanent cell lines from the tumor tissue of 4 patients and immunodetection of nestin and CD133 was performed on these cell lines. Results: Nestin-positive tumor cells were immunohistochemically detected in all of the examined osteosarcomas, but the proportion of these cells that were positively stained as well as the intensity of staining varied. Nestin-positive cells were rarely observed in 2 tumor samples, and the remaining 16 tumor samples showed various nestin expression patterns ranging from very sporadic occurrence to an overwhelming proportion of cells with strong positive staining. Three of the established osteosarcoma cell lines were demonstrated to be nestin-positive, and only one cell line showed no expression of nestin; this finding corresponds with the rare occurrence of nestin-positive cells in the respective tumor sample. Moreover, three of these osteosarcoma cell lines were undoubtedly proven to be Nes+/CD133+. Conclusion: Our results represent the first evidence of nestin expression in osteosarcomas and suggest the possible occurrence of cells with a stem-like phenotype in these tumors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Plant Sciences

Disruption of NAP1 genes in Arabidopsis thaliana suppresses the fas1 mutant phenotype, enhances genome stability and changes chromatin compaction

Karolina Kolarova, Martina Nespor Dadejova, Tomas Loja, Gabriela Lochmanova, Eva Sykorova, Martina Dvorackova

Summary: The disruption of the H2A-H2B histone chaperone NUCLEOSOME ASSEMBLY PROTEIN 1 (NAP1) can suppress the loss-of-function phenotype of FAS1, leading to wild-type growth, decreased sensitivity to genotoxic stress, and suppression of telomere and 45S rDNA loss in Arabidopsis thaliana. This study demonstrates the essential role of NAP1 proteins in DNA repair in the absence of functional CAF-1, which is coupled to nucleosome assembly through modulation of H3 levels in the nucleus.

PLANT JOURNAL (2021)

Article Genetics & Heredity

Spindle Cell Hemangioma and Atypically Localized Juxtaglomerular Cell Tumor in a Patient with Hereditary BRIP1 Mutation: A Case Report

Jan Papez, Jiri Starha, Pavel Zerhau, Denisa Pavlovska, Marta Jezova, Tomas Jurencak, Katerina Slaba, Martin Sterba, Arpad Kerekes, Tomas Merta, Terezia Haluskova, Hana Palova, Ondrej Slaby, Jaroslav Sterba, Petr Jabandziev

Summary: Spindle cell hemangioma and reninoma are extremely rare tumors in children and adolescents. Clinical diagnosis of the tumors requires consideration of factors such as pain level, family history, and secondary hypertension.
Article Hematology

FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia

Vaclav Seda, Eva Vojackova, Laura Ondrisova, Lenka Kostalova, Sonali Sharma, Tomas Loja, Gabriela Mladonicka Pavlasova, Daniel Zicha, Marie Kudlickova Peskova, Jan Krivanek, Kvetoslava Liskova, Leos Kren, Vladimir Benes, Katerina Musilova Litzmanova, Marek Borsky, Jan Oppelt, Jan Verner, Sarka Pospisilova, Yvona Brychtova, Anna Panovska, Zhi Tan, Shuxing Zhang, Michael Doubek, Katerina Amruz Cerna, Jiri Mayer, Marek Mraz

Summary: The migration and survival of CLL cells are influenced by GAB1, which can be targeted for therapeutic purposes, especially in combination with BTK inhibitors.
Article Oncology

Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy-Observational prospective single institution analysis

Peter Mudry, Michal Kyr, Ondrej Rohleder, Michal Mahdal, Iva Staniczkova Zambo, Marta Jezova, Tomas Tomas, Jaroslav Sterba

Summary: The study reported potential benefits of mifamurtide in conventional therapy and compared it to a historical control group. The results showed that adding mifamurtide had a significant progression-free survival benefit for localized osteosarcoma patients.

JOURNAL OF BONE ONCOLOGY (2021)

Article Public, Environmental & Occupational Health

Development of the Czech Childhood Cancer Information System: Data Analysis and Interactive Visualization

Denisa Krejci, Matej Karolyi, Lucie Pehalova, Jakub Scavnicky, Michaela Zapletalova, Ivana Katinova, Jaroslav Sterba, Jan Stary, Lenka Snajdrova, Martin Komenda, Ladislav Dusek

Summary: The study developed a new web portal called the Czech Childhood Cancer Information System to provide information on childhood cancer epidemiology in the country. By validating data from multiple sources, the portal offers basic information on childhood cancer including incidence, mortality, and overall survival rates through interactive reports.

JMIR PUBLIC HEALTH AND SURVEILLANCE (2021)

Article Engineering, Biomedical

Risk factors for tumors or leukemia development in the first two years of life

Hana Wiedermannova, Peter Mudry, Jan Pavlicek, Hana Tomaskova, Andrea Hladikova, Hana Palova, Petra Vesela, Ondrej Slaby, Jaroslav Sterba

Summary: This study aimed to determine the incidence and risk factors of neoplastic diseases in the early stages of life. The results identified medications used by the mother before or during pregnancy and genetic diseases as the highest risk factors for early childhood tumors.

BIOMEDICAL PAPERS-OLOMOUC (2023)

Review Oncology

Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

Andrew D. J. Pearson, Claudia Rossig, Crystal Mackall, Nirali N. Shah, Andre Baruchel, Gregory Reaman, Rosanna Ricafort, Delphine Heenen, Abraham Bassan, Michael Berntgen, Nick Bird, Eric Bleickardt, Najat Bouchkouj, Peter Bross, Carrie Brownstein, Sarah Beaussant Cohen, Teresa de Rojas, Lori Ehrlich, Elizabeth Fox, Stephen Gottschalk, Linda Hanssens, Douglas S. Hawkins, Ivan D. Horak, Danielle H. Taylor, Courtney Johnson, Dominik Karres, Franca Ligas, Donna Ludwinski, Maksim Mamonkin, Lynley Marshall, Behzad K. Masouleh, Yousif Matloub, Shannon Maude, Joe McDonough, Veronique Minard-Colin, Koen Norga, Karsten Nysom, Alberto Pappo, Laura Pearce, Rob Pieters, Martin Pule, Alfonso Quintas-Cardama, Nick Richardson, Martina Schuessler-Lenz, Nicole Scobie, Martina A. Sersch, Malcolm A. Smith, Jaroslav Sterba, Sarah K. Tasian, Brenda Weigel, Susan L. Weiner, Christian Michel Zwaan, Giovanni Lesa, Gilles Vassal

Summary: The seventh multi-stakeholder Paediatric Strategy Forum discussed the use of chimeric antigen receptor (CAR) T-cells in pediatric cancer treatment. The development of CAR T-cells for patients with haematological malignancies, especially B-cell precursor acute lymphoblastic leukaemia (BCP-ALL), has been successful. However, there are challenges in using CAR T-cells for other pediatric malignancies such as acute myeloid leukaemia (AML), lymphomas, and solid tumors. The forum aimed to summarize the current landscape, identify challenges and future directions, and determine the best strategies to accelerate the development and availability of CAR T-cell therapy for children. The forum emphasized the importance of improving efficacy, exploring alternative targets, and engaging academia and industry to advance cellular immunotherapies in pediatric oncology.

EUROPEAN JOURNAL OF CANCER (2022)

Article Biochemistry & Molecular Biology

Iron-Chelation Treatment by Novel Thiosemicarbazone Targets Major Signaling Pathways in Neuroblastoma

Peter Macsek, Jan Skoda, Maria Krchniakova, Jakub Neradil, Renata Veselska

Summary: Novel thiosemicarbazones show promise in targeting MYCN-amplified and non-amplified neuroblastoma by reducing N-MYC and c-MYC expression, and decreasing total EGFR levels and phosphorylation through the involvement of NDRG1, a positive prognostic marker in neuroblastoma.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Oncology

Final results of the Choroid Plexus Tumor study CPT-SIOP-2000

Johannes E. Wolff, Stefaan W. Van Gool, Tezer Kutluk, Blanca Diez, Rejin Kebudi, Beate Timmermann, Miklos Garami, Jaroslav Sterba, Gregory N. Fuller, Brigitte Bison, Uwe R. Kordes

Summary: Standards for chemotherapy against choroid plexus tumors have not yet been established. In this study, Carboplatin/Etoposide/Vincristine (CarbEV) was found to be more effective than Cyclophosphamide/Etoposide/Vincristine (CycEV). Histological grading was the most influential prognostic factor.

JOURNAL OF NEURO-ONCOLOGY (2022)

Article Biochemistry & Molecular Biology

Thiosemicarbazones Can Act Synergistically with Anthracyclines to Downregulate CHEK1 Expression and Induce DNA Damage in Cell Lines Derived from Pediatric Solid Tumors

Silvia Paukovcekova, Maria Krchniakova, Petr Chlapek, Jakub Neradil, Jan Skoda, Renata Veselska

Summary: This study identified a new mechanism for overcoming multidrug resistance in anticancer therapy. By combining anthracyclines with thiosemicarbazones, synergistic effects were observed in cell types derived from pediatric solid tumors. The synergism was independent of Pgp expression and resulted from impaired DNA repair control leading to cell death. The concomitant application of these drugs achieved the strongest synergistic effect with lower concentrations.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Pharmacology & Pharmacy

Thiosemicarbazones and selected tyrosine kinase inhibitors synergize in pediatric solid tumors: NDRG1 upregulation and impaired prosurvival signaling in neuroblastoma cells

Maria Krchniakova, Silvia Paukovcekova, Petr Chlapek, Jakub Neradil, Jan Skoda, Renata Veselska

Summary: This study analyzed the effects of combining three TKIs and two iron-chelating agents in the treatment of pediatric solid tumors. The results showed that the combination of these drugs had synergistic and/or additive effects, inhibiting cell signaling and inducing apoptosis. The combination of lapatinib with the iron-chelating agents had the most significant effects. These findings provide a rationale for the novel strategy of combining iron-chelating agents with TKIs in the therapy of pediatric solid tumors.

FRONTIERS IN PHARMACOLOGY (2022)

Article Oncology

European regulatory strategy for supporting childhood cancer therapy developments

Dominik Karres, Giovanni Lesa, Franca Ligas, Sylvie Benchetrit, Sara Galluzzo, Karen Van Malderen, Jaroslav Sterba, Maaike van Dartel, Marleen Renard, Peter Sisovsky, Siri Wang, Koen Norga

Summary: Regulatory decisions on paediatric investigation plans (PIPs) are crucial for providing effective and safe medicines for children with unmet medical needs, particularly in the field of paediatric oncology. Coordinating with stakeholders is essential for prioritizing and accelerating drug development in this challenging area.

EUROPEAN JOURNAL OF CANCER (2022)

Meeting Abstract Biochemistry & Molecular Biology

A link between the p53 pathway and cancer stemness-associated transcription factors in childhood sarcomas: MDM2 positively correlates with c-MYC and KLF4

L. Curylova, J. Neradil, M. Kyr, R. Veselska, J. Skoda

FEBS OPEN BIO (2022)

Article Oncology

Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)-Exploring Its Possible Clinical Relevance in Cancer Patients

Michal Rihacek, Iveta Selingerova, Ivo Kocak, Ilona Kocakova, Eva Rihackova, Dalibor Valik, Jaroslav Sterba

Summary: This study retrospectively analyzed the data of adult and pediatric patients treated with sunitinib, and found that sunitinib treatment increased the mean corpuscular volume of erythrocytes. The study also found that the rate of increase was faster in patients who experienced treatment-related adverse events.

CURRENT ONCOLOGY (2022)

Article Oncology

Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing

Petra Pokorna, Giannoula Lakka Klement, Alzbeta Vasikova, Veronika Kanderova, Marta Jezova, Kristyna Noskova, Peter Mudry, Michal Kyr, Tomas Merta, Viera Bajciova, Zdenka Krenova, Hana Palova, Dalibor Valik, Lenka Zdrazilova Dubska, Ondrej Slaby, Jaroslav Sterba

JCO PRECISION ONCOLOGY (2022)

暂无数据